Trial · NCT05267600
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 24 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Percent Change of Total IgG Serum Levels From Baseline Over Time | up to 36 weeks | |
| Secondary | Percent Change of Anti-BP180 and Anti-BP230 Antibodies From Baseline Over Time | up to 36 weeks | |
| Secondary | Incidence of Antidrug Antibodies Against Efgartigimod and Antibodies Produced Against rHuPH20 | up to 46 weeks | |
| Secondary | Number of Participants (or Their Caregivers) Who Are Determined by Site Staff to be Sufficiently Competent in (Self-)Administering Efgartigimod PH20 SC | up to week 32 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05267600/registered?page=2